胰腺癌是当今世界上死亡率最高的肿瘤之一.以其早期症状不明显、诊断手段缺乏、肿瘤标志物不特异、容易发生早期淋巴结转移以及晚期难以手术治愈而被称为"癌中之王".由于胰腺癌手术治疗晚期癌症疗效不佳及对放化疗方案的耐药性,目前对于胰腺癌靶向治疗的研究越来越多.L1细胞黏附分子(L1CAM)是细胞黏附分子免疫球蛋白超家族中的一员,通常表达于正常的神经组织中.近年来的研究表明,L1CAM在胰腺癌细胞中表达异常增多,并且可以与α5-integrin结合,作用于下游TGF-β1/JUK/slug通路,激活下游肿瘤侵袭转移相关因子,介导肿瘤细胞的上皮间质转化(epithelial-mesenchymal tromsition,EMT)、耐药性以及异常血管生成等方面的效应,从而促进胰腺癌细胞的侵袭转移.因此,深入的研究和实验或许可以促进胰腺癌未来的治疗发展,为胰腺癌提供一个新的治疗手段.%Pancreatic cancer has the highest mortality among malignant cancers. Known as"the king of cancer,"it lacks early symp-toms, diagnostic methods and oncologic markers. Early lymph node metastasis could be found in this disease. Moreover, advanced panereatic cancer is incurable by surgery. Due to the limited efficacy of surgery, as well as radiotherapy and chemotherapy tolerance, therapeutic methods for pancreatic cancer are being explored. L1 cell adhesion molecule (L1CAM) is a member of the cell adhesion molecule inmunoglobulin (Ig) super family that is usually expressed in normal developing nervous tissues. L1CAM is highly expressed in pancreatic cancer cells, binds withα5-integrin to activate downstream factors that mediate tumor metastasis and invasion via the TGF-β1/JUK/slug signaling pathway, induces epithelium-mesenchymal transition, and resists chemotherapy drugs. However, L1CAM forms abnormal vessels that increase the invasiveness of pancreatic cancer cells. This abnormal L1CAM expression in pancreatic can-cer cells is a new therapeutic target in pancreatic cancer treatment. Therefore, future studies on L1CAM could promote the develop-ment of pancreatic cancer therapy and provide new treatment methods.
展开▼
